INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
INOVIO Pharmaceuticals filed an 8-K on November 17, 2026 (reporting period November 13, 2026) disclosing Item 5.02 matters concerning departure of directors or officers and compensatory arrangements. The filing metadata indicates these matters occurred, but the specific document text with names, amounts, dates, and details of the departure or arrangements is not provided in the filing header or accessible portions submitted.
Why this rating
Officer/director changes are routine corporate filings. Without specific details (identity, severance amounts, replacement named, or material financial terms), and given INOVIO's modest $74.3M market cap, the event appears administrative. If substantial severance or leadership vacuum exists, significance could rise materially.
Extracted items
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.